Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...

Moderna will showcase detailed melanoma results for Intismeran at ESMO, alongside data and trial updates exploring the personalized therapy in pancreatic and lung cancers.

President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Personalized cancer vaccines are attracting growing attention as advances in mRNA technology open up new possibilities across oncology.

The biotech is entering a new era.

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be. That approach just cleared its ...